Recalls of generic Zantac believed to be contaminated by a carcinogen continue to flood in. Two other firms have declared recalls of ranitidine heartburn meds in 150 mg and 300 mg doses. The news arrived even as the degree of the drug returns increased with Mylan’s impromptu recall of three lots of nizatidine capsules last week because the API in them also held dangerous levels of NDMA.
Shortly after the Federal officials announced the voluntary recalls of some pharmacies over NDMA, a drug filled with a potential human carcinogen, many other pharmacies have recalled the common variety of heartburn drug Zantac, called ranitidine, from shelves.
Additional generic editions of Zantac are being taken down from pharmacy shelves after officials detected low levels of a possible carcinogens in the heartburn medication.
The Stryker Tritanium Acetabular Shell, which restores the human hip socket, is built from a titanium alloy covered with a unique kind of porous foam. The foam enables bone cells to bind with it and grow, thereby increasing joint stability. However, a 2018 report in the journal Arthroplasty Today by doctors at NYU Langone Orthopedic Hospitals described five hip implant failures related to Stryker’s Tritanium cups between 2011 and 2016.
The Catholic Church continues to deal with the fallout from this summer’s shocking grand jury investigation into allegations of rampant sexual abuse by clergy members in several dioceses throughout Pennsylvania. In the latest update, two survivors of alleged child sexual abuse have sued the Philadelphia Archdiocese in order to obtain records of misconduct by priests, along with their work histories.
The Philadelphia Diocese of the Catholic Church has announced that it has created a compensation fund for victims of clergy sexual abuse. The new reparations plan, announced yesterday, will be called the Independent Reconciliation and Reparations program, and will be run by a team responsible for a similar fund in New York.
A new study indicates what many within the healthcare industry have increasingly come to suspect about IVC (Inferior Vena Cava) filters: the device is not associated with a reduction in patient mortality. At the same time, the implantation of the filters during catheter-based lytic therapy procedures has significantly increased treatment costs. It seems patients and their insurance providers are paying a lot of money for very little in the way of results.
2332 South Broad Street
Philadelphia PA 19145
p: 215 462 3330 / f: 215-567-1941
